Cas:16646-44-9 Glyoxal bis(diallyl acetal) manufacturer & supplier

Chemical Name:Glyoxal bis(diallyl acetal)

CAS.NO:16646-44-9

Synonyms:3-[1,2,2-tris(prop-2-enoxy)ethoxy]prop-1-ene;3-[1,2,2-tris(allyloxy)ethoxy]prop-1-ene;Glyoxal bis(diallyl acetal);1-Propene, 3,3′,3”,3”’-[1,2-ethanediylidenetetrakis(oxy)]tetrakis-;3-[1,2,2-Tris(allyloxy)ethoxy]-1-propene;MFCD00043927;3,3′,3”-((Allyloxy-1-ethanyl-2-ylidene)tris(oxy))trispropene;1-Propene, 3,3′,3”-(((2-propenyloxy)-1-ethanyl-2-ylidene)tris(oxy))tris-;1,1,2,2-Tetrakis(allyloxy)ethane;EINECS 240-692-3

Molecular Formula:C₁₄H₂₂O₄

Molecular Weight:254.322

HS Code:2909199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:297.0±35.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.459

PSA:36.92000

Exact Mass:254.151810

LogP:4.61

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 3-[1,2,2-tris(prop-2-enoxy)ethoxy]prop-1-ene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 240-692-3 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-[1,2,2-Tris(allyloxy)ethoxy]-1-propene Use and application,EINECS 240-692-3 technical grade,usp/ep/jp grade.

Related News: Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules. Glyoxal bis(diallyl acetal) manufacturer Thank you for being open” about the diagnosis, NBC’s chief foreign affairs correspondent and anchor Andrea Mitchell wrote to Amanpour on Twitter. “It is so important and typical of how strong and brave you’ve always been. Courage and honesty is your trademark. You will beat this too. Glyoxal bis(diallyl acetal) supplier The firm also has several lawyers whose reputations would carry weight with the Justice Department and the FDA, including former Attorney General Eric Holder, legal experts said. Gerald Masoudi, the Covington partner who handled the recent inquiry for Lilly, once served as the FDA’s chief counsel. Masoudi did not respond to requests for comment. Glyoxal bis(diallyl acetal) vendor With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. Glyoxal bis(diallyl acetal) factory In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.